<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936958</url>
  </required_header>
  <id_info>
    <org_study_id>405</org_study_id>
    <nct_id>NCT04936958</nct_id>
  </id_info>
  <brief_title>RETR(Osteomyelitis)</brief_title>
  <official_title>RETR(Osteomyelitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective study describing the management of osteomyelitis in a referece&#xD;
      center, with success and failures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic osteomyelitis is a serious osteoarticular infection that most often occurs in the&#xD;
      long bones (tibia, femur, humerus), responsible for significant morbidity with the risk of&#xD;
      fracture and amputation. It is caused by the presence of bacteria in the bone marrow,&#xD;
      sometimes responsible for an intraosseous abscess. Chronic osteomyelitis can have a&#xD;
      hematogenous or more often exogenous origin, after trauma or surgery.&#xD;
&#xD;
      Despite the progress made in both antibiotics and surgical treatment, the probability of&#xD;
      failure of this treatment (infectious recurrence) is of the order of 20%, and has&#xD;
      unfortunately remained stable for more than 20 years.&#xD;
&#xD;
      An innovative treatment, Cerament-G (BONESUPPORT AB Laboratory, Sweden), a synthetic bone&#xD;
      substitute composed of hydroxyapatite, calcium sulphate, and gentamicin (CE marking), fills&#xD;
      the &quot;dead space&quot; which is formed during surgery, prevents this cavity filled with blood from&#xD;
      becoming infected, and promotes the regeneration of the bone within this space, limiting the&#xD;
      risk of fracture in the medium and long term. It also locally delivers very high doses of&#xD;
      gentamicin for several weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of osteomyelitis in BJI</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>proportion of patients having had an osteomyelitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>site of osteomyelitis</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>localisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone defect size</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>dimension of the bone defect size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>type of osteomyelitis</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>hematogenous or after a trauma or after a surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of bacteria involved in osteomyelitis</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>description of bacteria responsible for osteomyelitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of patients</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>comorbidities, age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the follow up of the patients</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>duration of the follow up of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>description of patients : medical treatment</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>description and duration of antibiotics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of patients : surgical treatment</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>description of surgery performed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of patient treated with CERAMENT</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>proportion of patients having had CERAMENT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of treatment failure</measure>
    <time_frame>between 2017 and 2021</time_frame>
    <description>treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteomyelitis</condition>
  <arm_group>
    <arm_group_label>patients having had an osteomyelitis since 2017</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients having had an osteomyelitis since 2017</intervention_name>
    <description>description of osteomyelitis and their management</description>
    <arm_group_label>patients having had an osteomyelitis since 2017</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who presented with osteomyelitis between 2017 and 2021 managed at the CRIOAc Lyon&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who presented with osteomyelitis between 2017 and 2021&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who objected to participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Tristan Ferry, Md,PhD</last_name>
    <phone>04 26 73 29 38</phone>
    <email>tristan.ferry@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugenie Mabrut, CRA</last_name>
    <phone>04 26 73 29 38</phone>
    <email>eugenie.mabrut@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenie Mabrut, CRA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.crioac-lyon.fr/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematogenous</keyword>
  <keyword>bone substitute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

